How to Assess the Clinical Impact of Left Ventricular Thrombus

To the editor, Left ventricular thrombus (LVT) is associated not only with systemic thromboembolism but also with bleeding complications due to the inevitable need for anticoagulation therapy. In the present study, the authors developed and validated a novel mortality prediction model for patients with LVT, using a large single-center retrospective cohort 1. While this represents an important step forward, several concerns deserve further discussion. The authors identified several risk factors for all-cause mortality, including hypoalbuminemia, elevated B-type natriuretic peptide level, absence of anticoagulation, history of stroke, and malignancy 1. However, these variables appear to reflect the general prognosis of patients with advanced heart failure or systemic illness, rather than being specific to LVT 2. For example, hypoalbuminemia is widely recognized as a marker of frailty and poor outcomes in cardiovascular disease. Similarly, B-type natriuretic peptide elevation reflects hemodynamic burden rather than LVT per se. The added prognostic value of incorporating LVT into these models, compared with established heart failure cohorts without LVT, remains unclear. In this regard, cardiovascular-specific endpoints such as stroke, systemic embolism, or major adverse cardiovascular events may be more appropriate to assess the unique prognostic impact of LVT. Therapeutic strategies require clarification. The study showed that direct oral anticoagulants were associated with the most favorable outcomes, followed by low-molecular-weight heparin and warfarin 1. Yet, details of anticoagulation duration, intensity of warfarin control (time in therapeutic range), and criteria for its discontinuation were not described. Since current guidelines often recommend anticoagulation for 3–6 months with repeat imaging to guide continuation 3, it would be informative to know how many patients received prolonged versus time-limited therapy and whether recurrent events clustered after anticoagulation withdrawal. Surgical thrombectomy represents another treatment modality that may have major prognostic implications but was not discussed in the present study. Recurrence of LVT deserves attention. The authors primarily evaluated mortality 1, but for many clinicians, prevention of recurrence is equally important in guiding anticoagulation strategy. Recurrence risk likely differs by etiology: in non-ischemic cardiomyopathy, reverse remodeling following optimal medical therapy may promote thrombus resolution and reduce recurrence, whereas in ischemic cardiomyopathy, scar-related akinesis or aneurysm often persists, predisposing to recurrent thrombus after discontinuation of therapy. Stratified analysis by underlying cardiomyopathy type might therefore provide more practical insights. The diagnostic approach warrants further comment. Although echocardiography was the primary diagnostic tool in the present study 1, cardiac magnetic resonance imaging has higher sensitivity and specificity for detecting mural thrombi and may improve risk stratification. Future studies incorporating multimodality imaging may better define the true incidence and prognostic weight of LVT. The authors have nothing to report. The authors declare no conflicts of interest. The manuscript does not include any original data.